The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO),
Despite the notion of investing in the healthcare sector as a safe haven, the following six companies (APPY, CMED, CYPB, DSCO, MYL, PFE) are all down sharply over the past year despite solid underlying fundamentals, which are largely unaffected by global economic conditions.
Diagnostics
China Medical (CMED) is trading near its IPO levels of August 2005 despite excellent growth prospects and a PEG ratio of 0.3X, a forward PE of 8X, and a dividend yield of 1.8%. For some perspective on the velocity of the downturn in CMED, the stock
We are going to give China Medical (CMED) another try on the long side. Volume is non existent in this market so it is impossible to trust any moves, but this stock was absolutely hammered once they did their convertible announcement [Aug 12: China Medical Announces Convertible Debt Offering] and now will have a standing short position sitting in there (shorting common stock versus convertible holding) so we'll see if CMED can move up into that. But we have a nice low risk entry on the chart.
I don't know what is going on with these charts of late but they continue to disagree on stockchar...
Many investors have found that in this turbulent market, gains often come in the “two steps forward, one step back” variety. Such is the case with China Medical Technologies, Inc., (CMED) over the past two weeks. The company announced earnings August 4th after the close which sent the stock sprinting higher. But a week later, on the 12th, management announced it would be issuing $150 million worth of convertible senior notes along with additional stock (or American Depository Receipts - ADS). The news sent the stock tumbling back down and after the deal was priced at $48.00 the stock co
Many investors have found that in this turbulent market, gains often come in the “two steps forward, one step back” variety. Such is the case with China Medical Technologies, Inc. (ADR), (CMED) over the past two weeks. The company announced earnings August 4th after the close which sent the stock sprinting higher. But a week [...]
I'll stick a limit order at the top of this gap and see if we can snag it on an inevitable pullback.
So instead of chasing it up in the $53s, or $54 - I placed a 300 limit share order @ $50.50 which hit late yesterday. I added another 100 shares this AM in a similar price level. There...
After some perceived hiccups the last 2 quarters, which in retrospect proved to be a great buying opportunity as the market overreacted to a 90 day (quarterly) period of time, China Medical (CMED) appears to be back on track judging from yesterday's earnings. The stock has taken some lumps earlier this year, and the last time around a lower gross margin rate and higher tax rates raised some concerns. Some of those concerns seem to have been alleviated with yesterday's numbers. Even more interesting to me, is the subtle shift in revenue stream to diagnostic reagents versus medical equipment...
China Medical Technologies, Inc. (ADR) (CMED) and its often cited cousin Mindray Medical International Limited (MR) have both had more than their share of volatility this year. But on a relative basis, China Medical appears to be a better value with a more optimistic future. That may help to explain why China Medical [...]
China Medical Technologies (CMED) is a fast growing Chinese in-vitro diagnostic [IVD] company that possesses a compelling business model and low cost operations to take advantage of Chinas continuing urbanization and rising incomes.
This company has adept management and strong ties to various research institutions in China that allowed it to develop a high margin and recurring revenue product base that bodes well for growth not only in China but also in other areas throughout Southeast Asia, Europe and the United States. In its young history China Medical exhibited devotion
What does a company do when your primary product line begins to saturate the market you operate in? If you are China Medical Technologies (CMED), you are likely to expand in to new markets both geographically, and in relation to products offered. For some time the company focused on marketing its HIFU (High Intensive Focused [...]
What does a company do when your primary product line begins to saturate the market you operate in? If you are China Medical Technologies (CMED), you are likely to expand in to new markets both geographically, and in relation to products offered. For some time the company focused on marketing its HIFU (High Intensive Focused [...]
Bullish "Mojo Crossover"! Get on the list for our "Hot Conference" chat room and trade with Mojo and 100 fellow traders coming soon (1st 100)! Just send an email (Subject: Hot Conference) http://modj97-predictwallstreet.blogspot.com The blog has updated charts for today's trading too.
This company develops, manufactures and sells hi-tech medical equipment of various sorts. They can even cure cancer :) CMED has been generating 50 % profit (on average!) and grows 50 % per year, and it does pay dividends. Earnings per share for 2005, 2006 and 2007: 0.59, 0.79 and 1.06. Consensus EPS estimates for 2008 and 2009: 1.65 and 2.15. China Medical Technologies is a frequent talker in respectable conferences, and they have deals with major Chinese hospitals. For example: "China Medical Technologies to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and M...
Since I wrote about China Medical Tech's (CMED) growth strategies more than three months ago, several developments have been announced. And the following is what I think particularly noteworthy.
1. The company's recent acquisiton of FISH (Fluorescent in situ Hybridization) technology enables it to enter a huge and virtually untapped Chinese market.
The potential market for prenatal genetic defects diagnostics alone is 1.6 million patients. And that for cervical cancer diagnostics could be as many as 5.76 million patients (120,000 in Shanghai city alone). Were affordability not a...
Data powered by QuoteMedia.
All Rights Reserved.
Data delayed 15 to 20 minutes unless otherwise indicated.
Terms of Use.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
